Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients (pts) with carcinoma of unknown primary site (CUP): Results of a prospective Sarah Cannon Research Institute (SCRI) trial.

Frank A. Greco, John D. Hainsworth, Ralph V. Boccia et al.|Journal of Clinical Oncology|2012

Cited by 4